Clinical Cancer Research 2018-Jul
Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Ссылка сохраняется в буфер обмена
Ключевые слова
абстрактный
Higher concentrations of TKIs, such as pazopanib, are associated with improved outcomes in advanced RCC. A phase III trial failed to show disease-free survival benefit to pazopanib in the adjuvant setting, but improved DFS was seen in patients with higher Ctrough levels, supporting adequate drug exposure for optimal clinical outcome. Clin Cancer Res; 24(13); 2979-80. ©2018 AACRSee related article by Sternberg et al., p. 3005.